FTC Orders Illumina to Divest Cancer Detection Test Maker Grail

The US Federal Trade Commission on Monday ordered Illumina to divest cancer diagnostic test maker Grail, finding that its ownership would stifle competition in the US market for cancer tests.
Reuters Health Information

source https://www.medscape.com/viewarticle/990377?src=rss

Comments

Popular posts from this blog

Student Nurses Who Refuse Vaccination Struggle to Complete Degrees

The Clinical Characteristics of Fractures in Pediatric Patients Exposed to Proton Pump Inhibitors